Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.

ABSTRACT:

Introduction

Monoclonal anti-amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD).

Methods

In the DIAN-TU-001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [¹¹C]-Pittsburgh compound-B (PiB) positron emission tomography (PET), [¹⁸F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI).

Results

Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. Drug effects were a

SUBMITTER: McCullough A 

PROVIDER: S-EPMC12260115 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature